Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.61 |
| ▸ | TACR3 | P29371 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24855511 | 0.92 | OPRM1 (0.52) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24230841 | 0.88 | OPRM1 (0.46) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL9910972 | 0.84 | OPRM1 (0.71) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4630038 | 0.83 | OPRM1 (0.61) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855392 | 0.81 | TACR3 (0.49) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL3410403 | 0.77 | OPRM1 (1.00) | OPRM1OPRL1 | |
| SCHEMBL3742048 | 0.76 | TACR3 (0.62) | OPRM1OPRL1TACR3 | |
| SCHEMBL3751174 | 0.76 | TACR3 (0.62) | OPRM1OPRL1TACR3 | |
| SCHEMBL6022898 | 0.75 | OPRM1 (0.51) | OPRM1OPRL1TACR3CYP3A4CYP2D6 | |
| SCHEMBL2333169 | 0.75 | HRH3 (0.54) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147134-A2 | METHODS FOR TREATING PATIENTS HAVING LOW ESTROGEN WITH NK3 ANTAGONISTS | ACER THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147135-A1 | NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER | ACER THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023278843-A2 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |